Bettie W Kareko1, Brian L Booty2, Chad D Nix3, Zoe L Lyski1, Mark K Slifka1,4, Ian J Amanna5, William B Messer1,6,7. 1. Department of Molecular Microbiology and Immunology, Portland. 2. Oregon Clinical and Translational Research Institute, Portland. 3. Department of Infection Prevention and Control, Portland. 4. Division of Neuroscience, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton. 5. Najit Technologies, Inc., Beaverton, Oregon. 6. Division of Infectious Diseases, Department of Medicine, Oregon Health & Science University,, Portland. 7. OHSU-PSU School of Public Health, Oregon Health and Science University.
Abstract
BACKGROUND: The once-in-a-lifetime recommendation for vaccination against yellow fever virus (YFV) has been controversial, leading to increased scrutiny of the durability of immunity after 17D vaccination. METHODS: This is a cross-sectional analysis of 17D vaccinees living in nonendemic Portland, Oregon. Neutralization assays were used to determine YFV immunity. The relationships between 17D immunity and vaccination history, demographics, and travel were evaluated using nominal logistic regression. RESULTS: Seventy-one of 92 (77.2%) subjects were YFV seropositive (90 percent plaque reduction neutralization test ≥1:10) at all timepoints, and 24 of 38 (63.8%) were YFV seropositive at ≥10 years after single-dose vaccination. No relationship was found between YFV immunity and time in endemic countries, other flavivirus immunity, or demographics. Subjects were most likely to become seronegative between 3 and 12 years postvaccination (logistic regression, odds ratio [OR] = 1.75; 95% confidence interval [CI], 1.12-2.73). A comparison of our results and 4 previous studies of YFV nonendemic vaccinees found that overall, 79% (95% CI, 70%-86%) of vaccinees are likely to be seropositive ≥10 years postvaccination. CONCLUSIONS: These results suggest that 1 in 5 17D vaccinees will lack neutralizing antibodies at ~10 years postvaccination, and a booster vaccination should be considered for nonendemic vaccinees before travel to regions where there is a high risk of YFV transmission.
BACKGROUND: The once-in-a-lifetime recommendation for vaccination against yellow fever virus (YFV) has been controversial, leading to increased scrutiny of the durability of immunity after 17D vaccination. METHODS: This is a cross-sectional analysis of 17D vaccinees living in nonendemic Portland, Oregon. Neutralization assays were used to determine YFV immunity. The relationships between 17D immunity and vaccination history, demographics, and travel were evaluated using nominal logistic regression. RESULTS: Seventy-one of 92 (77.2%) subjects were YFV seropositive (90 percent plaque reduction neutralization test ≥1:10) at all timepoints, and 24 of 38 (63.8%) were YFV seropositive at ≥10 years after single-dose vaccination. No relationship was found between YFV immunity and time in endemic countries, other flavivirus immunity, or demographics. Subjects were most likely to become seronegative between 3 and 12 years postvaccination (logistic regression, odds ratio [OR] = 1.75; 95% confidence interval [CI], 1.12-2.73). A comparison of our results and 4 previous studies of YFV nonendemic vaccinees found that overall, 79% (95% CI, 70%-86%) of vaccinees are likely to be seropositive ≥10 years postvaccination. CONCLUSIONS: These results suggest that 1 in 5 17D vaccinees will lack neutralizing antibodies at ~10 years postvaccination, and a booster vaccination should be considered for nonendemic vaccinees before travel to regions where there is a high risk of YFV transmission.
Authors: Martin S Cetron; Anthony A Marfin; Kathleen G Julian; Duane J Gubler; Donald J Sharp; Rachel S Barwick; Leisa H Weld; Robert Chen; Richard D Clover; Jaime Deseda-Tous; Victor Marchessault; Paul A Offit; Thomas P Monath Journal: MMWR Recomm Rep Date: 2002-11-08
Authors: Rebecca M Casey; Jennifer B Harris; Steve Ahuka-Mundeke; Meredith G Dixon; Gabriel M Kizito; Pierre M Nsele; Grace Umutesi; Janeen Laven; Olga Kosoy; Gilson Paluku; Abdou S Gueye; Terri B Hyde; Raimi Ewetola; Guylain K M Sheria; Jean-Jacques Muyembe-Tamfum; J Erin Staples Journal: N Engl J Med Date: 2018-02-14 Impact factor: 91.245
Authors: Vanessa Wolff Machado; Pedro Fernando da Costa Vasconcelos; Eliana Vieira Pinto Silva; João Barberino Santos Journal: Rev Soc Bras Med Trop Date: 2013 Mar-Apr Impact factor: 1.581
Authors: Tini Garske; Maria D Van Kerkhove; Sergio Yactayo; Olivier Ronveaux; Rosamund F Lewis; J Erin Staples; William Perea; Neil M Ferguson Journal: PLoS Med Date: 2014-05-06 Impact factor: 11.069
Authors: Leah C Katzelnick; Jose Victor Zambrana; Douglas Elizondo; Damaris Collado; Nadezna Garcia; Sonia Arguello; Juan Carlos Mercado; Tatiana Miranda; Oscarlett Ampie; Brenda Lopez Mercado; César Narvaez; Lionel Gresh; Raquel A Binder; Sergio Ojeda; Nery Sanchez; Miguel Plazaola; Krista Latta; Amy Schiller; Josefina Coloma; Fausto Bustos Carrillo; Federico Narvaez; M Elizabeth Halloran; Aubree Gordon; Guillermina Kuan; Angel Balmaseda; Eva Harris Journal: Sci Transl Med Date: 2021-10-06 Impact factor: 17.956